AstraZeneca to issue fixed-rate, floating-rate notes in four parts

By Devika Patel

Knoxville, Tenn., Aug. 14 – AstraZeneca plc intends to offer notes in four tranches, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be sold in three fixed-rate tranches due 2023, 2029 and 2048 and one floating-rate tranche due 2023.

The fixed-rate notes will have make-whole calls and par calls. The floaters will be non-callable.

Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. and J.P. Morgan Securities LLC are the bookrunners.

Proceeds will be used for general corporate purposes, including debt repayment.

The biopharmaceutical company is based in Cambridge, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.